1353644-50-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific targeting and therapeutic properties.
Used in Chemical Research:
1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is also utilized in chemical research as a model for studying the reactivity and behavior of cyclopropane rings and their derivatives. It can provide insights into the mechanisms of various chemical reactions and help in the design of new synthetic pathways.
Used in Antidepressant Development:
1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is used as a precursor in the development of selective norepinephrine and serotonin reuptake inhibitors, such as Milnacipran. These drugs are approved for the management of fibromyalgia and can potentially be used to treat other conditions related to neurotransmitter imbalances.
Used in Impurity Analysis:
As an impurity of Milnacipran (M344600), 1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is important in the quality control and regulatory processes of the pharmaceutical industry. Its analysis and control ensure the safety and efficacy of the final drug product.

Upstream product

• 172016-06-7 (1R,2S)-1-phenyl-2-(hydroxymethyl)-N,N-diethylcyclopropanecarboxamide 
• 140-29-4 phenylacetonitrile 
• 109-89-7 diethylamine 
• 63106-93-4 (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 
• 172015-99-5 (1 S,2 R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide 

Relevant academic research and scientific papers

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Preparation method of levomilnacipran hydrochloride

The invention relates to the field of chemical medicines and organic synthesis and in particular relates to a preparation method of levomilnacipran hydrochloride. Aiming at solving the problems of anexisting method for preparing the levomilnacipran hydrochloride that the cost is relatively high or a generation process is relatively dangerous so that large-scale industrial production is limited, the preparation method is characterized by comprising the following steps: [1] enabling phenylacetonitrile and (R)-2-chloromethyl ethylene oxide to react under the action of sodium amide to obtain a compound 1; then carrying out hydrolysis cyclization on the compound 1 to obtain a compound 2; [2] enabling the compound 2 and thionyl chloride to react in alcohol, so as to obtain a compound 3; [3] enabling the compound 3 to be subjected to exchange reaction through introducing nitryl and amino, so as to obtain a compound 6; [4] reducing nitryl in the compound 6 and forming salt in situ to obtain the levomilnacipran hydrochloride. The preparation method provided by the invention is applicable to industrial production of the levomilnacipran hydrochloride.

Preparation method of levomilnacipran hydrochloride

The invention provides a preparation method of levomilnacipran hydrochloride. According to the preparation method, a mixed liquid is obtained through a mixed reaction of a compound adopting the structure shown in the formula (II) and alkali; then acid is

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS

The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers of formula (I) or its pharmaceutically acceptable salt thereof wherein R1 and R2 are represents independently selected from the group consisting of hydrogen, lower alkyl, lower aryl, and lower-alkylaryl, which aryl or alkylaryl group is optionally substituted by a halogen atom.

Synthesis and characterization of process related impurities of (±)-Milnacipran

Milnacipran is a cyclopropane derivative, used as an anti depressant drug. During the process development of milnacipran, four process related potential impurities were detected in high performance liquid chromatography. All these impurities were identified, synthesized and subsequently characterized by their respective spectral data (IR, LC-MS, 1HNMR, and 13C NMR) as described in this article.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of neurological conditions may he formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may he used to treatment: of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multipie sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

PROCESS FOR THE PREPARATION OF (±M1R(S), 2SRR)L-2-(AMINOMETHYL)-N,N-DIETHYL-L-PHENYLCYCLOPROPANE CARBOXAMIDE HYDROCHLORIDE

The present invention relates to an improved process for the preparation of (±)-[1R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-l-phenylcyclopropane carboxamide hydrochloride compound of formula- la.

Enantioselective synthesis of levomilnacipran

A novel approach for the asymmetric synthesis of the active (1S,2R)-enantiomer of the antidepressant milnacipran is reported. The two stereogenic centers borne by the cyclopropane ring were sequentially installed starting from phenylacetic acid.